Zimmer Biomet Holdings, Inc. ($ZBH)

The Veterans SPORT Act (S.3138) mandates VA coverage of adaptive prostheses for sports, creating a new guaranteed procurement stream for prosthetic manufacturers. $ZBH is the best-positioned pure-play beneficiary with direct prosthetic product lines, while $BAX sees secondary rehabilitative equipment demand. The bill has cleared committee and awaits floor action, with $ZBH down -10.64% in 7 days, presenting a potential entry point ahead of legislative momentum.

→ Creates a new guaranteed procurement stream from the VA for adaptive sports prosthetics, increasing demand for specialized prosthetic product lines by an amount proportional to the eligible veteran population seeking sports-related activities

S. 2981 mandates a centralized VA Prosthetic Formulary, creating a durable government procurement channel for medical device makers. Direct beneficiaries Zimmer Biomet ($ZBH) and Stryker ($SYK) have both sold off sharply in the past week, but the bill's bipartisan momentum and committee passage signal a potential catalyst. No specific funding amount is authorized in the bill text, so actual revenue depends on subsequent contract awards.

→ VA must create a standardized, nationwide procurement channel for prosthetic and rehabilitative items, consolidating purchasing from fragmented local contracts to a single formulary-driven system.

The Medicare Orthotics and Prosthetics Patient-Centered Care Act (S. 2329) prohibits Medicare payment for drop-shipped O&P devices without in-person practitioner involvement. This structurally shifts market share from commoditized drop-ship suppliers toward credentialed custom-fitted device manufacturers. The bill is early-stage but has a House companion and is sponsored by Sen. Warner (D-VA), giving it moderate legislative momentum.

→ Competitive bidding exempts credentialed practitioners (orthotists, prosthetists) and requires in-person fitting, shifting Medicare billable volume from anonymous drop-ship suppliers to qualified practitioners and the manufacturers of custom-fitted devices they prescribe.

The HEAR Act of 2025 is an early-stage, unfunded bill with no Senate companion, no committee hearing, and no markup. It proposes Medicare coverage for hearing aids, which would expand the total addressable market for hearing health, but no publicly traded pure-play hearing aid companies are represented in the provided ticker list. The bill has zero legislative momentum and zero appropriated funding, making it a non-event for current market pricing.

HR4475 is an early-stage bill that bans Medicare payment for drop-shipped orthotics and prosthetics, forcing patient fitting by qualified practitioners. This protects established providers like $ZBH and $STRR from low-cost mail-order competition but faces a long legislative path with zero direct federal funding attached.

→ Eliminates low-cost, mail-order drop-ship models that undercut established providers on price; shifts volume toward in-person, practitioner-guided fittings at higher reimbursement per unit. Expands the exempt provider pool, reducing competitive bidding downward pressure on pricing for custom devices.